Saturday 17 October 2026
Export GNPX’s income statement to Excel — free account
GENPREX
GNPX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.0% and free cash flow fell 33.0%, each against the same quarter a year earlier.
2.11
0.18
−7.86%
Follow GNPX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (203.86%) | (160.84%) | (338.73%) | (1,378.59%) |
+8 more TTM periods Free account |
|
| (157.40%) | (127.12%) | (227.24%) | (448.99%) | ||
ROIC |
0.00% | 0.00% | (7,402.48%) | 0.00% | |
Return on Tangible Assets |
(122.20%) | (108.26%) | (262.51%) | 2,004.45% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(32.90) | (45.17) | (360.26) | (435.91) | |
Free Cash Flow |
(15.56) | (14.29) | (15.31) | (15.08) | |
| Other line items | |||||
Cash ROIC |
(51.96%) | (40.85%) | (96.95%) | (806.07%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.94 | 0.85 | 0.94 | 0.90 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(32.90) | (45.17) | (360.26) | (435.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates